Peter Buggisch - Concepedia

Author

Peter Buggisch

Also Known As

Buggisch, Peter, Janina Trauth, P BUGGISCH, P Buggisch, P. Buggisch, P. Büggisch, P.B. Buggisch, PETER BUGGISCH, Peter Buggisch

475

Publications

12.8K

Citations

H-Index

Concepts

All Affiliations

Goethe University Frankfurt Medizinische Hochschule Hannover Institute for Interdisciplinary Medicine Universität Hamburg Charité - Universitätsmedizin Berlin

About

Peter Buggisch is an author at Goethe University Frankfurt specializing in medicine, hepatitis, and viral hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	42	4.2K
2	Health Sciences	1	1	549
3	Cell Biology	1	1	28
4	Emergency Medicine	1	1	95
5	Epidemiology	1	1	122

Peter Buggisch

Publications

11.2K

Citations

H-Index

Page 1

	Year	Citations
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection Nezam H. Afdhal, Stefan Zeuzem, Paul Y. Kwo, New England Journal of Medicine	2014	1.7K
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B Patrick Marcellin, E. Jenny Heathcote, Ed Gane, New England Journal of Medicine	2008	1.2K
Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma G. Riethmüller, Rudolf Gruber, E. Schneider-Gädicke, The Lancet Surgical OncologyGastrointestinal OncologyMedicineImmunologyColorectal Cancer	1994	638
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection Marc Bourlière, Stuart C. Gordon, Steven L. Flamm, New England Journal of Medicine	2017	558
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ). Marion G. Peters, Hie‐Won Hann, Paul Martin, Gastroenterology	2003	553
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study Armando Santoro, Lorenza Rimassa, Ivan Borbath, The Lancet Oncology Second-line TreatmentPlacebo-controlled Phase 2OncologyHepatologyMedicine	2012	549
Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin Thomas Berg, Michael Wagner, Samer Nasser, Gastroenterology Peginterferon-alfa-2a Plus RibavirinHepatologyHepatitis CVersus 72Viral Hepatitis	2006	519
Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. G. Riethmüller, E Holz, Günter Schlimok, Journal of Clinical Oncology	1998	516
Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B E. Jenny Heathcote, Patrick Marcellin, Edward Gane, Gastroenterology HepatologyViral HepatitisMedicineHepatitis BHepatitis	2010	461
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B Karsten Wursthorn, Marc Lütgehetmann, Maura Dandri, Hepatology	2006	438

Page 1